Skip to content

Digital Intervention Targeting Cancer-related Cognitive Impairments

Digital Intervention Targeting Cancer-related Cognitive Impairments

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06693102
Enrollment
60
Registered
2024-11-18
Start date
2025-01-02
Completion date
2028-01-02
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Cognitive Impairment

Keywords

cancer survivors, cancer-related cognitive impairments, cognitive remediation, cognitive training, cognitive challenges

Brief summary

Cognitive deficits are frequently reported following cancer treatment and can significantly impact daily functioning. These cognitive impairments often persist for years after cancer treatment. This study aimed to examine several aspects of a newly developed digital intervention designed to address cognitive impairments. Specifically, it focused on: (1) evaluating the preliminary effects of the intervention, (2) identifying predictors of treatment response, (3) assessing the feasibility of both the intervention and the study design, (4) gathering participant feedback on the intervention, and (5) testing the applicability of the Norwegian version of the Working Memory Questionnaire within this patient group.

Detailed description

Many cancer survivors report cognitive challenges, including problems with concentration, attention, memory, processing speed, and executive functions. These cognitive impairments can persist for years after cancer treatment and are associated with reduced functioning at home and work. Several approaches for managing cognitive difficulties are described in the literature. One approach is drill-and-practice interventions involving repetitive cognitive training, often employing computer-based tasks that increase in difficulty. Other interventions focus on strategy-based exercises, teaching patients to apply coping strategies in everyday situations. Additionally, psychoeducation is an important component in treating cognitive impairments. Access to interventions for cognitive impairments remains limited. This limited may be a consequence of limited healthcare professionals resources. One potential solution is to offer digital interventions. The research literature shows that digital interventions are as effective as face-to-face treatment for mental health conditions such as anxiety and depression. In a previous study, we also found that digital interventions for cognitive impairments in depression, to be feasible. Offering digital interventions for cancer-related cognitive impairments might therefore be a promising approach for addressing one of the most common late effects following cancer treatment. This study aims to assess the preliminary effects and the feasibility of a digital intervention for cancer-related cognitive impairments. Specifically, it aims to reduce self-reported cancer-related cognitive impairments. Additionally, we will examine whether the intervention increase performance on objectively measured cognitive tests. Other outcomes are rumination, life satisfaction, fatigue, depressive symptoms, and anxiety symptoms. Qualitative feedback from participants on their experience with the intervention will be used to refine the program. We will also assess the feasibility of a recently translated questionnaire for measuring working memory in this patient group. The study will include 60 cancer survivors. Thirty of these will receive the digital intervention and 30 will receive paper and pencil crossword and sudoku tasks. The research questions are: 1. What preliminary changes in self-reported cognitive impairments and other clinical outcomes are observed among cancer survivors after receiving the digital intervention? 2. To what extent do clinical and demographic factors influence the usage and response to a digital intervention for cognitive impairments following cancer treatment? 3. How feasible is the newly developed digital intervention for cognitive impairments? 4. How do cancer survivors experience a newly developed digital intervention for cognitive impairments? 5. How effective is the translated version of the Working Memory Assessment Questionnaire in measuring cognitive impairments among Norwegian cancer survivors?

Interventions

BEHAVIORALDigital intervention targeting cancer-related cognitive impairments

The intervention is developed using a person-centered approach and includes key components such as psychoeducation, cognitive training, compensatory strategy training, and cognitive restructuring exercises. Participants receive weekly remote support from a therapist and are encouraged to complete the program within a six-week period.

BEHAVIORALCrossword and sudoku taks

Participants receive crossword and sudoku tasks. They are encourraged to solve such tasks for a minimum of 15 minutes daily for six weeks.

Sponsors

The Research Council of Norway
CollaboratorOTHER
Haukeland University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Participants are not randomized before all pre-assessment questionnaires and tests are completed.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

The target group consists of individuals who have previously undergone cancer treatment (N=60). Inclusion Criteria: 1. Age between 18 and 65 years, 2. Self-reported cognitive difficulties that are perceived to impact daily functioning (PCI \<44 FACT-Cog), 3. Have received cancer treatment, 4. Completed curative treatment at least six months prior, 5. Proficient in speaking and writing Norwegian, 6. Access to a computer, tablet, or smartphone, and the internet.

Exclusion criteria

1. Neurological disorders (e.g., ADHD, MS, autism), 2. History of severe head injury, 3. Current moderate or severe depression (PHQ-9 score \>14), 4. Previously diagnosed with serious mental disorders, such as substance abuse, bipolar disorder, or psychotic disorders.

Design outcomes

Primary

MeasureTime frameDescription
The Functional Assessment of Cancer Therapy- Cognitive Functionpre-assessment to two-year follow-upThe Functional Assessment of Cancer Therapy- Cognitive Function (FACT-Cog) is a validated questionnaire consisting of 37 items designed to assess cognitive difficulties in cancer survivors. It includes four subscales: perceived cognitive impairment, cognitive abilities, feedback from others, and the impact of cognitive decline on quality of life. Total scores ranges from 0-148. Higher scores indicate better cognitive function.

Secondary

MeasureTime frameDescription
Digit Span Wechsler Adult Intelligence Scale-IVPre- to six-month follow-up assessmentsDigit Span Wechsler Adult Intelligence Scale-IV measures auditory attention span and working memory. Numbers are read aloud to participants, who repeat the sequence. The sequence length increases, and participants also repeat sequences backward. This test

Other

MeasureTime frameDescription
The Functional Assessment of Chronic Illness Therapy-FatiguePre- to two years follow-up assessmentsThe Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT) is a 13-item questionnaire that assesses fatigue and its implications for daily functioning. Total scores ranges from 0 to 52. Higher scores represents less fatigue.
The Satisfaction with Life ScalePre-assessment to two-year follow-upThe The Satisfaction with Life Scale (SWLS) measure life satisfaction. Total scores ranges from 5-35. Higher scores indicate greater level of life satisfaction. This questionnaire consists of five items.
Credibility and Expectancy QuestionnaireFirst week after receiving the intervention.The Credibility and Expectancy Questionnaire (CEQ) measure treatment credibility and expectancy. The rating scale ranges from 0-10 where higher scores indicate better credibility and expectancy.
Rumination response scalepre- to two year follow-up assessmentRumination response scale (RRS) consists of 22 items measuring aspects of rumination. Total scores ranges from 22-88. Higher scores indicate greater levels of rumination. The RRS can be divided into three subscales: depression-related thoughts, brooding, and reflection.
Color-Word Interference Test Delis-Kaplan Executive Function SystemPre- to six month follow-up assessments.The Color-Word Interference Test, from the Delis-Kaplan Executive Function System battery (D-KEFS), consists of four subtests. Two conditions measure processing speed and mental efficiency, where participants say the ink color of squares and read color names in black ink. The following conditions measure inhibition and focus-shifting, with one condition requiring participants to say the ink color of incongruent words, and the last requiring participants to switch between naming ink color and reading color words depending on whether a frame surrounds the word.
Word and Category Fluency Delis-Kaplan Executive Function SystemPre- six month follow-up assessments.The Word and Category Fluency, from the Delis-Kaplan Executive Function System (D-KEFS), is a neuropsychological test measuring verbal fluency. The test has three conditions: producing words that start with certain letters, naming items within categories, and alternating between categories.
The Generalized Anxiety Disorder-7Pre-assessment to two-year follow-up.The Generalized Anxiety Disorder-7 (GAD-7) consists of seven items that measure symptoms of anxiety. Total scores ranges from 0-21. Higher scores indicating more symptoms of anxiety.
California Verbal Learning Test IIPre- to six-month follow-up assessments.The California Verbal Learning Test II (CVLT-II is a neuropsychological word list test measuring verbal short-term and long-term memory.
Patient Health Questionnaire-9Pre- to two-year follow-up assessmentPatient Health Questionnaire-9 (PHQ-9) onsists of nine items that assess depressive symptoms. Scores ranges from 0-27. Higher scores indicate more symptoms. .

Countries

Norway

Contacts

Primary ContactSunniva Brurok Myklebost, PhD
sunniva.brurok.myklebost@helse-bergen.no0047 55556767
Backup Contacttine Nordgreen, PhD
tine.nordgreen@helse-bergen.no0047 55 559862

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026